Joan Genescà

15.8k total citations · 3 hit papers
149 papers, 6.9k citations indexed

About

Joan Genescà is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Joan Genescà has authored 149 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Hepatology, 110 papers in Epidemiology and 45 papers in Surgery. Recurrent topics in Joan Genescà's work include Liver Disease Diagnosis and Treatment (100 papers), Liver Disease and Transplantation (89 papers) and Hepatitis C virus research (27 papers). Joan Genescà is often cited by papers focused on Liver Disease Diagnosis and Treatment (100 papers), Liver Disease and Transplantation (89 papers) and Hepatitis C virus research (27 papers). Joan Genescà collaborates with scholars based in Spain, Canada and United States. Joan Genescà's co-authors include Rafael Esteban, Salvador Augustín, Cristina Hernández, J. Guardia, Rafael Simó, Antonio González, Juan Ignacio Esteban, Marı́a Martell, Albert Lecube and Juan G. Abraldeṣ and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Annals of Internal Medicine.

In The Last Decade

Joan Genescà

145 papers receiving 6.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1992 777 citations Marı́a Martell, Juan Ignacio Esteban et al. profile →
HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN

1989 751 citations Rafael Esteban, Joan Genescà et al. The Lancet profile →
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

2019 392 citations Càndid Villanueva, Agustı́n Albillos et al. The Lancet profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Joan Genescà	5.9k	5.5k	1.6k	375	367	149	6.9k
Giorgio Maria Saracco	4.4k 0.8×	4.5k 0.8×	1.5k 1.0×	314 0.8×	369 1.0×	298	7.4k
Antonina Smedile	6.6k 1.1×	6.7k 1.2×	584 0.4×	302 0.8×	592 1.6×	199	8.1k
Miquel Bruguera	5.1k 0.9×	5.1k 0.9×	928 0.6×	209 0.6×	305 0.8×	177	7.2k
V. Di Marco	5.7k 1.0×	7.0k 1.3×	770 0.5×	1.0k 2.8×	343 0.9×	274	8.4k
Dominique Roulot	3.6k 0.6×	3.6k 0.7×	825 0.5×	275 0.7×	288 0.8×	112	4.9k
Takeji Umemura	2.5k 0.4×	3.0k 0.6×	1.2k 0.8×	234 0.6×	418 1.1×	223	4.8k
Alessandra Mangia	6.4k 1.1×	6.1k 1.1×	500 0.3×	306 0.8×	759 2.1×	202	7.7k
Savino Bruno	5.9k 1.0×	5.7k 1.0×	508 0.3×	220 0.6×	625 1.7×	133	7.0k
Jenny Heathcote	10.0k 1.7×	9.9k 1.8×	1.7k 1.1×	645 1.7×	843 2.3×	175	12.6k
G. Realdi	4.3k 0.7×	4.6k 0.8×	1.4k 0.9×	96 0.3×	450 1.2×	187	7.3k

Countries citing papers authored by Joan Genescà

Since Specialization

Citations

This map shows the geographic impact of Joan Genescà's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Genescà with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Genescà more than expected).

Fields of papers citing papers by Joan Genescà

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Genescà. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Genescà. The network helps show where Joan Genescà may publish in the future.

Co-authorship network of co-authors of Joan Genescà

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Genescà. A scholar is included among the top collaborators of Joan Genescà based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Genescà. Joan Genescà is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pons, Mònica, Thomas Reiberger, Mattias Mandorfer, et al.. (2025). Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis. Journal of Hepatology. 84(3). 543–553.

Pons, Mònica, Jesús Rivera‐Esteban, Calogero Cammà, et al.. (2025). The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease. Gastroenterology. 170(2). 385–394.

Pons, Mònica, et al.. (2024). Noninvasive Assessment of Portal Hypertension. Clinics in Liver Disease. 28(3). 401–415. 1 indexed citations

Villanueva, Càndid, Joan Genescà, Juan Carlos García‐Pagán, et al.. (2024). Progressive systemic inflammation precedes decompensation in compensated cirrhosis. JHEP Reports. 7(2). 101231–101231. 4 indexed citations

Ventura‐Cots, Meritxell, Yu Jun Wong, Joan Genescà, et al.. (2024). Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design. Hepatology Communications. 8(8). 2 indexed citations

Pons, Mònica, et al.. (2024). Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Hepatology Communications. 8(11).

Pericàs, Juan M., Nicholas A. Di Prospero, Quentin M. Anstee, et al.. (2023). Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials. Alimentary Pharmacology & Therapeutics. 57(9). 948–961. 4 indexed citations

Azkargorta, Mikel, Imma Raurell, Juan M. Pericàs, et al.. (2023). Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases. International Journal of Molecular Sciences. 24(15). 11904–11904. 3 indexed citations

Rivera‐Esteban, Jesús, Mònica Pons, Ramiro Manzano-Núñez, et al.. (2023). Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes. Gastroenterología y Hepatología (English Edition). 46(9). 682–691. 1 indexed citations

10.

Rowe, Ian, Càndid Villanueva, Ferràn Torres, et al.. (2023). Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial. Hepatology. 78(2). 530–539. 7 indexed citations

11.

Raurell, Imma, Diana Rafael, Fernanda Andrade, et al.. (2023). Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells. Pharmaceutics. 15(10). 2463–2463. 7 indexed citations

12.

Pons, Mònica, Jesús Rivera‐Esteban, Mang Ma, et al.. (2023). Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 22(8). 1637–1645.e9. 27 indexed citations

13.

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2021). Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology. 75(3). 589–599. 39 indexed citations

14.

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2019). β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 393(10181). 1597–1608. 392 indexed citations breakdown →

15.

Pons, Mònica, Sergio Rodríguez‐Tajes, Juan Ignacio Esteban, et al.. (2019). Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. Journal of Hepatology. 72(3). 472–480. 121 indexed citations

16.

García‐Lezana, Teresa, Imma Raurell, Miren Bravo, et al.. (2017). Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 67(4). 1485–1498. 101 indexed citations

17.

Martín–Llahí, Marta, Agustı́n Albillos, Rafael Bañares, et al.. (2017). Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. Gastroenterología y Hepatología (English Edition). 40(8). 538–580. 15 indexed citations

18.

Ventura‐Cots, Meritxell, Isabel Carmona, Carolina Moreno, et al.. (2017). Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therapeutic Advances in Gastroenterology. 11. 1756283X17743419–1756283X17743419. 11 indexed citations

19.

Pons, Mònica, Macarena Simón‐Talero, Laura Millán, et al.. (2016). Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease. Digestive and Liver Disease. 48(10). 1214–1219. 12 indexed citations

20.

Genescà, Joan, Juan Ignacio Esteban, Josep Quer, et al.. (1993). Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.. Gut. 34(2 Suppl). S62–S63. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact